Press release
Gram-Negative Bacterial Infection Market Focused towards Growth 2025
Global Gram-Negative Bacterial Infection Market: Snapshot
Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.
The burden is more alarming and critical in case of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Patients with MDR Gram-negative bacterial are known to have a higher mortality rate of about 30–70%. Unarguably, they cause higher mortality rates, prolonged hospital stays, and escalated cost of treatment, particularly for patients in intensive care units.
Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94
According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant reemerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years.
Global Gram-negative Bacterial Infection: Overview
The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.
Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94
The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the market.
Global Gram-negative Bacterial Infection: Infection-type Segmentation
On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms. A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.
Read Comprehensive Overview of Report @ https://www.tmrresearch.com/gram-negative-bacterial-infection-market
Global Gram-negative Bacterial Infection: Analysis of Treatment Options
In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.
Global Gram-negative Bacterial Infection: Competitive Landscape
Players in the global gram-negative bacterial market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.
Contact:
TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
Email: sales@tmrresearch.com
Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.
The burden is more alarming and critical in case of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Patients with MDR Gram-negative bacterial are known to have a higher mortality rate of about 30–70%. Unarguably, they cause higher mortality rates, prolonged hospital stays, and escalated cost of treatment, particularly for patients in intensive care units.
Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94
According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant reemerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years.
Global Gram-negative Bacterial Infection: Overview
The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.
Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94
The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the market.
Global Gram-negative Bacterial Infection: Infection-type Segmentation
On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms. A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.
Read Comprehensive Overview of Report @ https://www.tmrresearch.com/gram-negative-bacterial-infection-market
Global Gram-negative Bacterial Infection: Analysis of Treatment Options
In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.
Global Gram-negative Bacterial Infection: Competitive Landscape
Players in the global gram-negative bacterial market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.
Contact:
TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
Email: sales@tmrresearch.com
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
